DDInter1845 DDInter826
A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders (From AMA Drug Evaluations Annual, 1994, p311). Tranylcypromine is a racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine with the chiral centers both located on the cylopropane ring. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).
Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonylurea drug group, glipizide displays rapid absorption and onset of action with the shortest half-life and duration of action, reducing the risk for long-lasting hypoglycemia that is often observed with blood glucose-lowering agents. Glipizide was first approved by the FDA in 1994 and is available in extended-release tablets under the brand name Glucotrol®, as well as in combination with metformin under the brand name Metaglip®.
Tranylcypromine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Glipizide
Tranylcypromine {u} (Compound) causes {v} (Side Effect) Chills
Chills {u} (Side Effect) is caused by {v} (Compound) Glipizide
Tranylcypromine {u} (Compound) resembles {v} (Compound) Phenelzine
Phenelzine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Tranylcypromine {u} (Compound) resembles {v} (Compound) Phendimetrazine
Phendimetrazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Tranylcypromine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Glyburide
Glyburide {u} (Compound) resembles {v} (Compound) Glipizide
Tranylcypromine {u} (Compound) causes {v} (Side Effect) Chills
Chills {u} (Side Effect) is caused by {v} (Compound) Gliclazide
Gliclazide {u} (Compound) resembles {v} (Compound) Glipizide
Tranylcypromine {u} (Compound) causes {v} (Side Effect) Muscle spasms
Muscle spasms {u} (Side Effect) is caused by {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glipizide
Tranylcypromine {u} (Compound) causes {v} (Side Effect) Rash
Rash {u} (Side Effect) is caused by {v} (Compound) Glyburide
Glyburide {u} (Compound) resembles {v} (Compound) Glipizide
Tranylcypromine {u} (Compound) causes {v} (Side Effect) Syncope
Syncope {u} (Side Effect) is caused by {v} (Compound) Dexamethasone
Dexamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Tranylcypromine {u} (Compound) resembles {v} (Compound) Phenelzine
Phenelzine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glimepiride
Glimepiride {u} (Compound) resembles {v} (Compound) Glipizide
Tranylcypromine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Glipizide (Compound)
Tranylcypromine (Compound) causes Chills (Side Effect) and Chills (Side Effect) is caused by Glipizide (Compound)
Tranylcypromine (Compound) resembles Phenelzine (Compound) and Phenelzine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Tranylcypromine (Compound) resembles Phendimetrazine (Compound) and Phendimetrazine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Tranylcypromine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Glyburide (Compound) and Glyburide (Compound) resembles Glipizide (Compound)
Tranylcypromine (Compound) causes Chills (Side Effect) and Chills (Side Effect) is caused by Gliclazide (Compound) and Gliclazide (Compound) resembles Glipizide (Compound)
Tranylcypromine (Compound) causes Muscle spasms (Side Effect) and Muscle spasms (Side Effect) is caused by Esomeprazole (Compound) and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Glipizide
Tranylcypromine (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Glyburide (Compound) and Glyburide (Compound) resembles Glipizide (Compound)
Tranylcypromine (Compound) causes Syncope (Side Effect) and Syncope (Side Effect) is caused by Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Tranylcypromine (Compound) resembles Phenelzine (Compound) and Phenelzine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)